1 Brayf F,Laversanne M,Sung H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2024,74(3):229-263. 2 Sun K,Zhang B,Lei S,et al.Incidence,mortality,and disability-adjusted life years of female breast cancer in China,2022[J].Chin Med J(Engl),2024,137(20):2429-2436. 3 纪璟,姜鹏,王汉晋.保乳手术在乳腺癌不同分子亚型患者中的临床疗效对比及其术后复发因素的分析[J].华南国防医学杂志,2020,34(9):626-630. 4 贺新,彭书甲,师弘.乳腺癌患者原发灶与复发转移灶中ER、PR、HER-2及Ki-67表达异质性的回顾性分析[J].现代肿瘤医学,2023,31(9):1660-1665. 5 张豪亭,杨银涛,马宇杰,等.细胞骨架相关蛋白4在肾透明细胞癌中的表达及其临床意义[J].中国癌症防治杂志,2023,15(2):190-195. 6 Wang X,Xing L,Yang R,et al.The circACTN4 interacts with FUBP1 to promote tumorigenesis and progression of breast cancer by regulating the expression of proto-oncogene MYC[J].Mol Cancer,2021,20(1):91. 7 Tentler D,Lomert E,Novitskaya K,et al.Role of ACTN4 in tumorigenesis,metastasis,and EMT[J].Cells,2019,8(11):1427. 8 张馨文,王波,许果.程序性死亡受体-配体1、E-钙黏蛋白、N-钙黏蛋白、信号转导及转录激活因子3表达与胸腺癌预后的关系研究[J].实用医院临床杂志,2022,19(4):51-56. 9 金梅,袁春雷,段思佳,等.趋化因子C-C-基元配体5对乳腺癌干细胞增殖和侵袭的影响研究[J].中国临床药理学杂志,2021,37(8):1000-1003. 10 向左娟,胡晓杰,陈小娟,等.基于生物信息学寻找乳腺癌干细胞上皮间充质转换的关键调节基因[J].湖南师范大学学报(医学版),2022,19(2):51-55. 11 Beck B,Blanpain C.Unravelling cancer stem cell potential[J].Nat Rev Cancer,2013,13(10):727-738. 12 Peng L,Zhang Z,Zhao D,et al.Discordance in ER,PR,HER2,and Ki-67 expression between primary and recurrent/metastatic lesions in patients with primary early stage breast cancer and the clinical significance:retrospective analysis of 75 cases[J].Pathol Oncol Res,2021,27:599894. 13 Kim Yg,Yoon Yn,Choi Hs,et al.Breast cancer stem cells in HER2-negative breast cancer cells contribute to HER2-mediated radioresistance and molecular subtype conversion:clinical implications for serum HER2 in recurrent HER2-negative breast cancer[J].Oncotarget,2018,9(5):5811-5822. 14 Zhang L,Chen W,Liu S,et al.Targeting breast cancer stem cells[J].Int J Biol Sci,2023,19(2):552-570. 15 梁雪丽,廖海,苏丹柯.整合素在乳腺癌中应用的研究进展[J].医学综述,2022,28(6):1103-1107. 16 Ahmed Km,Pandita Rk,Singh Dk,et al.Beta1-integrin impacts Rad51 stability and DNA double-strand break repair by homologous recombination[J].Mol Cell Biol,2018,38(9):e00672-17. 17 毕月.乳腺癌放疗抵抗机制的研究进展[J].中国医学创新,2023,20(30):172-176. 18 Liu W,Zheng M,Zhang R,et al.RNF126-mediated MRE11 ubiquitination activates the DNA damage response and confers resistance of triple-negative breast cancer to radiotherapy[J].Adv Sci(Weinh),2023,10(5):e2203884. 19 Sriramulu S,Thoidingjam S,Chen W,et al.BUB1 regulates non-homologous end joining pathway to mediate radioresistance in triple-negative breast cancer[J].J Exp Clin Cancer Res,2024,43(1):163. 20 Zhang F,Zheng Z,Wang L,et al.PKC-zeta mediated reduction of the extracellular vesicles-associated TGF-beta1 overcomes radiotherapy resistance in breast cancer[J].Breast Cancer Res,2023,25(1):38. 21 Loi S,Michielss,Salgado R,et al.Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer:results from the FinHER trial[J].Ann Oncol,2014,25(8):1544-1550. 22 Kovacs A,Stenmark Tullberg A,Werner Ronnerman E,et al.Effect of radiotherapy after breast-conserving surgery depending on the presence of tumor-infiltrating lymphocytes:a long-term follow-up of the sweBCG91RT randomized trial[J].J Clin Oncol,2019,37(14):1179-1187. 23 Patwardhan Rs,Rai A,Sharma D,et al.Txnrd1 as a prognosticator for recurrence,metastasis and response to neoadjuvant chemotherapy and radiotherapy in breast cancer patients[J].Heliyon,2024,10(6):e27011. 24 Patwardhan RS,Sharma D,Sandur SK.Thioredoxin reductase:An emerging pharmacologic target for radiosensitization of cancer[J].Transl Oncol,2022,17:101341. 25 Pellizzari S,Bhat V,Athwal H,et al.PLK4 as a potential target to enhance radiosensitivity in triple-negative breast cancer[J].Radiat Oncol,2024,19(1):24. 26 常添添,段伟.再程放疗与热疗联合治疗复发性乳腺癌研究进展[J].中国辐射卫生,2024,33(5):615-620. 27 Andratschke N,Willmann J,Appelt AL,et al.European society for radiotherapy and oncology and european organisation for research and treatment of cancer consensus on re-irradiation:definition,reporting,and clinical decision making[J].Lancet Oncol,2022,23(10):e469-e478. 28 Oldenborg S,Rasch Crn,van Os R,et al.Reirradiation + hyperthermia for recurrent breast cancer en cuirasse[J].Strahlenther Onkol,2018,194(3):206-214. 29 安迪.放疗联合热疗在乳腺癌肺转移患者中的应用效果[J].医疗装备,2023,36(10):52-55. 30 白诗婷,吴亚军,吴稚冰.全身热疗抗恶性肿瘤的研究进展[J].浙江临床医学,2024,26(2):293-296. 31 Chen M,Xiao L,Jia H,et al.Stereotactic ablative radiotherapy and FAPalpha-based cancer vaccine suppresses metastatic tumor growth in 4T1 mouse breast cancer[J].Radiother Oncol,2023,189:109946. 32 罗波,张曲,郑红梅,等.SRT联合拉帕替尼治疗HER2阳性乳腺癌脑转移疗效及预后分析[J].实用肿瘤学杂志,2021,35(6):523-528. 33 郑佳俊,翟振宇,孙丽.瓦里安高分辨率多叶准直器叶片位置误差对肺肿瘤立体定向放疗剂量学影响[J].中华放射肿瘤学杂志,2021,30(9):930-935. 34 夏铀铀,武丹,范育伟,等.基于放疗前增强定位CT的影像组学预测非小细胞肺癌脑转移分次立体定向放疗的近期疗效[J].实用肿瘤杂志,2022,37(5):465-469. 35 陈晓亮,王豪杰,王红旗.分次立体定向放疗联合全脑放疗治疗乳腺癌脑转移患者的临床疗效[J].癌症进展,2024,22(8):881-884. |